Compare Crispr Therapeutics AG (CRSP) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Crispr Therapeutics AG trades at $53.93 (market cap $4.88B), while Direxion Daily TSLA Bull 2X Shares trades at $10.45 (market cap $3.97B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and Direxion Daily TSLA Bull 2X Shares is more actively traded (38,458,237 versus 2,861,747). Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Direxion Daily TSLA Bull 2X Shares for 15 Days on average.
| CRSP | TSLL | |
|---|---|---|
Market Cap | $4.88B | $3.97B |
Volume | 2,861,747 | 38,458,237 |
Sector | Health | Leveraged / Inverse |
52-Week High | $74.92 | $23.03 |
52-Week Low | $44.34 | $6.74 |
Typical Hold Time | 77 Days | 15 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
TSLL (Direxion Daily TSLA Bull 2X Shares ETF) trades at $10.56, up 4.04% today, with a neutral technical signal overall despite bullish moving averages. The leveraged ETF amplifies Tesla's daily returns, with recent momentum driven by Tesla's Cybercab event anticipation. Key support sits at $10 with resistance at $11, while RSI indicators show mixed signals between short-term overbought conditions and neutral medium-term momentum.
As a leveraged ETF tracking Tesla, TSLL offers amplified exposure but carries significant volatility risks from daily rebalancing effects. The fund's performance remains entirely dependent on Tesla's stock movements, with recent news highlighting both opportunity from Tesla events and the structural risks of holding leveraged products long-term during volatile periods.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
